TNSN05014A1 - Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 - Google Patents
Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1Info
- Publication number
- TNSN05014A1 TNSN05014A1 TNP2005000014A TNSN05014A TNSN05014A1 TN SN05014 A1 TNSN05014 A1 TN SN05014A1 TN P2005000014 A TNP2005000014 A TN P2005000014A TN SN05014 A TNSN05014 A TN SN05014A TN SN05014 A1 TNSN05014 A1 TN SN05014A1
- Authority
- TN
- Tunisia
- Prior art keywords
- mip
- alpha
- binding
- selective inhibitors
- piperidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un composé de formule (I) : Dans laquelle A, B, C, R1, R2, R3, R4, R5, R6, Q, W, Y et Z répondent aux définitions précitées, utile comme inhibiteur puissant et sélectif de la liaison de MIP-1alpha (CCL3) à son récepteur CCR1 présent sur des cellules inflammatoires et immunomodulatrices (de préférence les leucocytes et lymphocytes).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39710802P | 2002-07-18 | 2002-07-18 | |
PCT/IB2003/002876 WO2004009550A1 (fr) | 2002-07-18 | 2003-07-07 | Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison mip-1alpha a son recepteur ccr1 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN05014A1 true TNSN05014A1 (fr) | 2007-05-14 |
Family
ID=30770997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2005000014A TNSN05014A1 (fr) | 2002-07-18 | 2005-01-18 | Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 |
Country Status (24)
Country | Link |
---|---|
US (1) | US20040063759A1 (fr) |
EP (1) | EP1534677A1 (fr) |
JP (1) | JP2005537279A (fr) |
KR (1) | KR20050021497A (fr) |
CN (1) | CN1668592A (fr) |
AP (1) | AP2005003200A0 (fr) |
AR (1) | AR040583A1 (fr) |
AU (1) | AU2003242941A1 (fr) |
BR (1) | BR0312946A (fr) |
CA (1) | CA2492651A1 (fr) |
EC (1) | ECSP055547A (fr) |
HN (1) | HN2003000222A (fr) |
IL (1) | IL166010A0 (fr) |
IS (1) | IS7614A (fr) |
MA (1) | MA27326A1 (fr) |
MX (1) | MXPA05000380A (fr) |
OA (1) | OA12885A (fr) |
PA (1) | PA8575901A1 (fr) |
PE (1) | PE20040666A1 (fr) |
TN (1) | TNSN05014A1 (fr) |
TW (1) | TW200402416A (fr) |
UY (1) | UY27897A1 (fr) |
WO (1) | WO2004009550A1 (fr) |
ZA (1) | ZA200500067B (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399790B2 (en) | 2001-02-28 | 2008-07-15 | Konowalchuk Thomas W | Virucidal compositions |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
JP4723242B2 (ja) | 2002-06-12 | 2011-07-13 | ケモセントリックス インコーポレーティッド | 炎症および免疫障害治療用ccr1アンタゴニストとして使用するための1−アリール−4−置換ピペラジン誘導体 |
WO2004009588A1 (fr) * | 2002-07-18 | 2004-01-29 | Pfizer Products Inc. | Derives de piperidine bicycliques utilises comme antagonistes du recepteur de chimiokine ccr1 |
US8261062B2 (en) | 2003-03-27 | 2012-09-04 | Microsoft Corporation | Non-cryptographic addressing |
US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
US7230022B2 (en) | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
US7288563B2 (en) | 2004-02-19 | 2007-10-30 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
CA2558211C (fr) | 2004-03-03 | 2013-09-03 | Chemocentryx, Inc. | Heterocycles d'azote bicycliques et pontes |
US7929689B2 (en) | 2004-06-30 | 2011-04-19 | Microsoft Corporation | Call signs |
US20060167044A1 (en) * | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
US7620902B2 (en) | 2005-04-20 | 2009-11-17 | Microsoft Corporation | Collaboration spaces |
US7617281B2 (en) | 2005-04-25 | 2009-11-10 | Microsoft Corporation | System and method for collaboration with serverless presence |
US7660851B2 (en) | 2005-07-06 | 2010-02-09 | Microsoft Corporation | Meetings near me |
PT1907374E (pt) | 2005-07-26 | 2012-11-05 | Glaxo Group Ltd | Derivados de benzilpiperazina úteis para o tratamento de doenças gastrointestinais |
US7576106B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
US8086842B2 (en) | 2006-04-21 | 2011-12-27 | Microsoft Corporation | Peer-to-peer contact exchange |
US8069208B2 (en) | 2006-04-21 | 2011-11-29 | Microsoft Corporation | Peer-to-peer buddy request and response |
US8586571B2 (en) * | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20100168080A1 (en) * | 2008-12-17 | 2010-07-01 | Khamrai Uttam | Novel compounds useful as cc chemokine receptor ligands |
CN105829296A (zh) | 2013-12-18 | 2016-08-03 | 巴斯夫欧洲公司 | 带有亚胺衍生的取代基的唑类化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (fr) * | 1962-12-19 | |||
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
WO1997024325A1 (fr) * | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES |
CA2373942A1 (fr) * | 1999-05-18 | 2000-11-23 | Teijin Limited | Remedes ou prophylactase contre les maladies associees a des chimiokines |
AR028947A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
CN100413860C (zh) * | 2001-07-24 | 2008-08-27 | 匈牙利吉瑞大药厂 | 作为nmda受体拮抗剂的哌啶衍生物 |
-
2003
- 2003-06-17 PA PA20038575901A patent/PA8575901A1/es unknown
- 2003-07-07 OA OA1200500010A patent/OA12885A/en unknown
- 2003-07-07 AP AP2005003200A patent/AP2005003200A0/xx unknown
- 2003-07-07 KR KR10-2005-7000849A patent/KR20050021497A/ko not_active Application Discontinuation
- 2003-07-07 CA CA002492651A patent/CA2492651A1/fr not_active Abandoned
- 2003-07-07 BR BR0312946-2A patent/BR0312946A/pt not_active Application Discontinuation
- 2003-07-07 WO PCT/IB2003/002876 patent/WO2004009550A1/fr not_active Application Discontinuation
- 2003-07-07 JP JP2004522601A patent/JP2005537279A/ja active Pending
- 2003-07-07 EP EP03765230A patent/EP1534677A1/fr not_active Withdrawn
- 2003-07-07 AU AU2003242941A patent/AU2003242941A1/en not_active Abandoned
- 2003-07-07 MX MXPA05000380A patent/MXPA05000380A/es unknown
- 2003-07-07 CN CNA038170922A patent/CN1668592A/zh active Pending
- 2003-07-08 US US10/616,844 patent/US20040063759A1/en not_active Abandoned
- 2003-07-15 PE PE2003000705A patent/PE20040666A1/es not_active Application Discontinuation
- 2003-07-16 UY UY27897A patent/UY27897A1/es not_active Application Discontinuation
- 2003-07-16 AR AR20030102555A patent/AR040583A1/es unknown
- 2003-07-17 HN HN2003000222A patent/HN2003000222A/es unknown
- 2003-07-17 TW TW092119550A patent/TW200402416A/zh unknown
-
2004
- 2004-12-23 IS IS7614A patent/IS7614A/is unknown
- 2004-12-27 IL IL16601004A patent/IL166010A0/xx unknown
-
2005
- 2005-01-04 ZA ZA200500067A patent/ZA200500067B/en unknown
- 2005-01-18 EC EC2005005547A patent/ECSP055547A/es unknown
- 2005-01-18 MA MA28049A patent/MA27326A1/fr unknown
- 2005-01-18 TN TNP2005000014A patent/TNSN05014A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AP2005003200A0 (en) | 2005-03-31 |
MXPA05000380A (es) | 2005-03-31 |
AU2003242941A1 (en) | 2004-02-09 |
OA12885A (en) | 2006-09-15 |
KR20050021497A (ko) | 2005-03-07 |
CA2492651A1 (fr) | 2004-01-29 |
EP1534677A1 (fr) | 2005-06-01 |
BR0312946A (pt) | 2005-07-12 |
PA8575901A1 (es) | 2004-07-20 |
UY27897A1 (es) | 2004-02-27 |
US20040063759A1 (en) | 2004-04-01 |
WO2004009550A1 (fr) | 2004-01-29 |
ZA200500067B (en) | 2005-11-02 |
HN2003000222A (es) | 2004-11-23 |
IS7614A (is) | 2004-12-23 |
MA27326A1 (fr) | 2005-05-02 |
IL166010A0 (en) | 2006-01-15 |
CN1668592A (zh) | 2005-09-14 |
JP2005537279A (ja) | 2005-12-08 |
PE20040666A1 (es) | 2004-09-25 |
ECSP055547A (es) | 2005-03-10 |
TW200402416A (en) | 2004-02-16 |
AR040583A1 (es) | 2005-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05014A1 (fr) | Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 | |
TNSN05013A1 (fr) | Derives de piperidine bicycliques servant d'antagonistes du recepteur de chimiokine ccr1 | |
NO20061978L (no) | Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon | |
MA28432B1 (fr) | Antagonistes du recepteur de la chimiokine | |
CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
GEP20074152B (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
TR199701356A2 (xx) | L�kozit adhasyonu inhibit�rleri ve VLA-4-antagonistleri olarak heterosiklenler. | |
ES2160408T3 (es) | Trifluorfenil-triazolpirimidinas fungicidas. | |
HUP0500610A2 (hu) | Indazol-, benzotiazol- és benzoizotiazol-származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
SE0302486D0 (sv) | Novel compounds | |
DK0734381T3 (da) | Morpholin- og thiomorpholintachykininreceptorantagonister | |
NO20063380L (no) | Triazolderivater som vasopressinantagonister | |
ATE228111T1 (de) | M-amidinophenyl-analoga als faktor-xa-inhibitoren | |
DE602005012634D1 (en) | Arylsulfonylnaphthalinderivate als 5ht2a-antagonisten | |
RU2008127257A (ru) | Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов | |
ATE338461T1 (de) | Pyrazolpyrimidinfungizide | |
ECSP055912A (es) | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas | |
SE0302324D0 (sv) | Novel compounds | |
NO20052866L (no) | Imidazokinolinderivater som adenosin A3 reseptorligander | |
SE0302323D0 (sv) | Novel compounds | |
MEP19108A (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
BR0311333A (pt) | ésteres na posição 20 de camptotecinas | |
ATE246174T1 (de) | Tosylprolin-derivate als thymidylat-synthase inhibitoren | |
EA200101096A1 (ru) | Применение производных мадурафталазина в качестве ингибиторов провоспалительных цитокинов | |
CO5210926A1 (es) | Mezclas fungicidas |